AbioMed AB5000
This article was originally published in The Gray Sheet
Executive Summary
Circulatory support system formal launch commences at American Academy for Thoracic Surgery annual meeting in Toronto April 26. Abiomed previously offered only the system's console, which gives patients more mobility and is priced at a premium to its BVS5000 biventricular support system (1"The Gray Sheet" April 19, 2004, p. 23). The firm says it "will continue to sell BVS5000 blood pumps for use by those patients who are expected to recover heart function after a few days of bedside support" and expects it "to remain an important revenue source"...
You may also be interested in...
Abiomed To Upgrade IT Applications Of AB5000 Circulatory Support System
Abiomed President and CEO Michael Minogue says the IT experience he gained in 11 years at GE Medical Systems will help to differentiate the firm's circulatory support devices from their competitors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.